20.2 C
New York
Friday, June 5, 2026

Tag: biotech

newssourceFORcompanyinformationcontent1marketreleases

Greenland Mines Completes Site Visit to Sarfartoq Nd-Pr Rare Earth Magnet Project in Greenland; Prepares 2026 Field Program

CHARLOTTE, N.C., June 4, 2026 /PRNewswire/ -- Greenland Mines Ltd ("Greenland Mines" or the "Company") (Nasdaq: GRML) today announced that its Greenland operations team has...

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...

【COMPUTEX 2026】Compal Integrates Quantum Technology and AI – Partnering with Top Universities and Pharmaceutical Firms to Build a Biotech AI Platform

TAIPEI, June 4, 2026 /PRNewswire/ -- Compal Electronics (Compal; TWSE: 2324) showcases its landmark achievements in Quantum Technology and Advanced Artificial Intelligence (AI) at COMPUTEX...

/C O R R E C T I O N — Oberland Biotech GmbH/

In the news release, Oberland Biotech GmbH Secures CHF 2.5 Million Seed Funding Round to Accelerate Global Expansion in Biotechnology and Food Innovation, issued...

Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting

Assemblée Générale Mixte du 24 juin 2026 Modalités de mise à disposition des documents préparatoires à l’Assemblée

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

Taiwan Market Cap Reaches New High as TWSE Showcases AI Strengths at COMPUTEX

Transforming from an exchange to an accelerator; connecting international capital to Taiwan's next wave of AI innovationTAIPEI, June 3, 2026 /PRNewswire/ -- Taiwan's market...

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society...

Greenland Mines Appoints WSP Denmark to Continue Environmental Baseline Work at the Sarfartoq Rare Earth Project

CHARLOTTE, N.C., June 2, 2026 /PRNewswire/ -- Greenland Mines Ltd ("Greenland Mines" or the "Company") (Nasdaq: GRML) today announced that it has engaged WSP...

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiotech

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers